<DOC>
	<DOCNO>NCT02970747</DOCNO>
	<brief_summary>The objective non-interventional study ( NIS ) evaluate patient ' adherence persistence carfilzomib therapy combination lenalidomide dexamethasone adult patient multiple myeloma ( MM ) receive least one prior therapy real-life setting .</brief_summary>
	<brief_title>Non-interventional Study Kyprolis速 Combination With Revlimid速 Dexamethasone Patients With Multiple Myeloma</brief_title>
	<detailed_description>The dual combination lenalidomide ( Revlimid速 ) ( R ) dexamethasone ( ) ( Rd ) standard regimen treat MM patient receive least one prior therapy . Recently publish clinical data indicate next-generation proteasome inhibitor carfilzomib ( Kyprolis速 ) ( K ) may substantially change treatment paradigm patient relapse MM ( RMM ) . To compare efficacy safety carfilzomib combination Rd ( KRd ) dual combination therapy Rd , randomize , multicenter , open-label phase III study perform patient RMM ( ASPIRE , NCT01080391 ) .2 After cycle 18 , carfilzomib discontinue KRd arm , Rd administration continue thereafter disease progression . The trial meet primary endpoint progression-free survival ( PFS ) ( Hazard Ratio ( HR ) progression death , 0.69 ; p=0.0001 ) . Median PFS 26.3 month KRd treatment compare 17.6 month Rd treatment . The study demonstrate carfilzomib improves patient ' overall survival ( OS ) rate 24 month ( KRd , 73.3 % vs. Rd , 65.0 % ; HR death , 0.79 ; p=0.04 ) overall response rate ( ORR ) ( KRd , 87.1 % vs. Rd , 66.7 % ; p &lt; 0.001 ) . Objective assessment adverse event ( AEs ) patient-reported outcome ( PRO ) reveal benefit-risk ratio favorable three-drug combination KRd . Up , real-life data patient ' adherence , persistence , quality life ( QoL ) pattern use , effectiveness safety KRd regimen systematically collect analyze . Thus , market approval KRd treatment patient MM receive least one prior therapy , purpose CARO NIS evaluate patient ' adherence , persistence QoL well effectiveness safety KRd regimen real-life setting .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Aged 18 year old . Patients MM receive least one prior therapy . Indication treatment assess treat physician . Decision second subsequentline treatment combination therapy carfilzomib/ lenalidomide/ dexamethasone . Signed write informed consent . Criteria accord Summary Product Characteristics ( SmPC ) patient treat combination therapy carfilzomib/ lenalidomide/ dexamethasone . Contraindications accord SmPC patient treat combination therapy carfilzomib/ lenalidomide/ dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>